Table 1. Baseline characteristics of the study population (n = 209).
| Characteristics | NA-naïve (n = 71) | NA-experienced (n = 138) | P-value |
|---|---|---|---|
| Age (years), mean ± SD | 50.6 ± 11.9 | 50.9 ± 10.9 | 0.883 |
| Male, n (%) | 48 (67.6) | 100 (72.5%) | 0.464 |
| HBeAg positivity, n (%) | 27 (38.0) | 108 (78.3) | < 0.001 |
| HBV DNA (log copies/mL), mean ± SD | 6.4 ± 1.6 | 5.3 ± 1.9 | < 0.001 |
| ALT (U/L), mean ± SD | 108.2 ± 192.7 | 54.9 ± 80.0 | 0.028 |
| eGFR (mL/min/1.73 m2), mean ± SD | 93.4 ± 28.2 | 87.6 ± 20.7 | 0.096 |
| BMI (kg/m2), mean ± SD | 23.5 ± 2.9 | 23.8 ± 3.4 | 0.536 |
| Cirrhosis, n (%) | 39 (54.9) | 30 (21.7) | < 0.001 |
| DM, n (%) | 7 (9.9) | 16 (9.5) | 0.692 |
| HTN, n (%) | 13 (18.3) | 21 (15.3) | 0.581 |
| CKD, n (%) | 4 (5.6) | 12 (8.7) | 0.430 |
| Treatment regimen | < 0.001 | ||
| TDF monotherapy, n (%) | 71 (100.0) | 69 (50.0) | |
| TDF + ETV, n (%) | 0 (0.0) | 65 (47.1) | |
| TDF + LAM or Ldt, n (%) | 0 (0.0) | 4 (2.9) | |
| Follow up duration, median months (range) | 28.0 (24–33) | 30.0 (24–43) | 1.000 |
NA, nucleos(t)ide analogue; SD-standard deviation; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine transaminase; eGFR, estimated glomerular filtration rate; BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; CKD, chronic kidney disease; TDF, tenofovir disoproxil fumarate; ETV, entecavir; LAM, lamivudine; LdT, telbivudine.